Cambridge Research Biochemicals, based in Billingham, Teesside, UK, has teamed up with Durham University to carry out important health research. CRB manufactures custom peptides and custom antibodies for use in pharmaceutical and biotechnology research across the world and is now carrying out the work with Durham University as part of a twelve-month Knowledge Transfer Account (KTA) scheme.
Dr Ehmke Pohl, a structural biologist and Dr Steven Cobb, a specialist in peptide synthesis from Durham University will be able to investigate synthetic ways of producing the human chemokines family of proteins. Chemokines play a key role in the human immune response which makes them useful for researchers in the field of heart disease, cancer and allergies.
CRB already has a strong track record in working with academic institutions, being a member of a pan-European group as part of an EU funded Framework 7 R&D Programme (BIOSCENT) worth 6 Million Euros over five years investigating peptide scaffolds as heart patches.
CRB’s main aim has always been to improve its services, and therefore, help support medical science by providing high quality reagents such as peptides.
|